Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2021 Dec 13;10(5):1238–1246. doi: 10.1016/j.jaip.2021.11.028

Table V.

β-coefficients for IV-Mg treatment using propensity score adjusted multivariable linear regression models to predict change of severity measured using the Acute Asthma Intensity Research Score

Propensity-score Adjusted Model β-coefficient a 95% CI P value
PS covariate adjusted b 0.98 0.20, 1.77 0.015
Inverse probability of treatment weighting b 0.89 0.27, 1.52 0.006
1:n matching on propensity score c 0.93 0.17, 1.68 0.017
1:1 forced matching on propensity score c 0.73 −0.17, 1.62 0.114

Abbreviations: PS, propensity score

a

β-coefficient for IV-Mg treatment. Positive β-coefficient indicates increased exacerbation severity during the 2-hour interval.

b

Covariates: PS, pre-treatment AAIRS, clinician making treatment decisions, clinician making disposition decision, age, gender, race, ethnicity, insurance type, prior PICU admission for asthma, treatment with CCS prior to ED arrival, and treatments in the first 2 hours of care including IV-Mg, BiPAP, albuterol by nebulizer, albuterol by MDI, parenteral epinephrine, and parenteral terbutaline

c

Covariates same as PS covariate adjusted model except PS